Literature DB >> 23388724

JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody.

Maximilian Larena1, Natalie A Prow, Roy A Hall, Nikolai Petrovsky, Mario Lobigs.   

Abstract

JE-ADVAX is a new, delta inulin-adjuvanted, Japanese encephalitis (JE) candidate vaccine with a strong safety profile and potent immunogenicity that confers efficient immune protection not only against JE virus but also against related neurotropic flaviviruses such as West Nile virus. In this study, we investigated the immunological mechanism of protection by JE-ADVAX vaccine using knockout mice deficient in B cells or CD8(+) T cells and poor persistence of neutralizing antibody or by adoptive transfer of immune splenocyte subpopulations. We show that memory B cells induced by JE-ADVAX provide long-lived protection against JE even in the absence of detectable pre-exposure serum neutralizing antibodies and without the requirement of CD8(+) T cells. Upon virus encounter, these vaccine-induced memory B cells were rapidly triggered to produce neutralizing antibodies that then protected immunized mice from morbidity and mortality. The findings suggest that the extent of the B-cell memory compartment might be a better immunological correlate for clinical efficacy of JE vaccines than the currently recommended measure of serum neutralizing antibody. This may explain the paradox where JE protection is observed in some subjects even in the absence of detectable serum neutralizing antibody. Our investigation also established the suitability of a novel flavivirus challenge model (β(2)-microglobulin-knockout mice) for studies of the role of B-cell memory responses in vaccine protection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23388724      PMCID: PMC3624336          DOI: 10.1128/JVI.03144-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).

Authors:  A P West; P J Bjorkman
Journal:  Biochemistry       Date:  2000-08-15       Impact factor: 3.162

Review 2.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn.

Authors:  V Ghetie; E S Ward
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 3.  Japanese encephalitis vaccines: current vaccines and future prospects.

Authors:  T P Monath
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

4.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

Authors:  Yoshikazu Honda-Okubo; Fadi Saade; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

Review 5.  Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.

Authors:  L Markoff
Journal:  Vaccine       Date:  2000-05-26       Impact factor: 3.641

6.  Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice.

Authors:  Rosa M Licon Luna; Eva Lee; Arno Müllbacher; Robert V Blanden; Rod Langman; Mario Lobigs
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses.

Authors:  C H Pan; H W Chen; H W Huang; M H Tao
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  beta2-microglobulin-associated regulation of interferon-gamma and virus-specific immunoglobulin G confer resistance against the development of chronic coxsackievirus myocarditis.

Authors:  Karin Klingel; Jens-Jörg Schnorr; Martina Sauter; Gudrun Szalay; Reinhard Kandolf
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

9.  Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations.

Authors:  Eiji Konishi; Tomoyuki Suzuki
Journal:  Vaccine       Date:  2002-11-22       Impact factor: 3.641

10.  Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice.

Authors:  Eiji Konishi; Naoko Ajiro; Chiyoko Nukuzuma; Peter W Mason; Ichiro Kurane
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

View more
  31 in total

1.  The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions.

Authors:  Peter D Cooper; Thomas G Barclay; Milena Ginic-Markovic; Nikolai Petrovsky
Journal:  Glycobiology       Date:  2013-07-12       Impact factor: 4.313

2.  A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection.

Authors:  Yoshikazu Honda-Okubo; Annasaheb Kolpe; Lei Li; Nikolai Petrovsky
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

3.  DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.

Authors:  Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

4.  Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.

Authors:  David Gordon; Peter Kelley; Susanne Heinzel; Peter Cooper; Nikolai Petrovsky
Journal:  Vaccine       Date:  2014-09-27       Impact factor: 3.641

Review 5.  Zika virus vaccines.

Authors:  Peter Abbink; Kathryn E Stephenson; Dan H Barouch
Journal:  Nat Rev Microbiol       Date:  2018-10       Impact factor: 60.633

6.  Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

Authors:  Yoshikazu Honda-Okubo; Dale Barnard; Chun Hao Ong; Bi-Hung Peng; Chien-Te Kent Tseng; Nikolai Petrovsky
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

7.  Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain.

Authors:  Amanda E Calvert; Kandice L Dixon; Mark J Delorey; Carol D Blair; John T Roehrig
Journal:  Vaccine       Date:  2013-11-17       Impact factor: 3.641

8.  Inulin isoforms differ by repeated additions of one crystal unit cell.

Authors:  Peter D Cooper; Thomas G Barclay; Milena Ginic-Markovic; Andrea R Gerson; Nikolai Petrovsky
Journal:  Carbohydr Polym       Date:  2013-12-31       Impact factor: 9.381

9.  Inulin crystal initiation via a glucose-fructose cross-link of adjacent polymer chains: atomic force microscopy and static molecular modelling.

Authors:  Peter D Cooper; K Harinda Rajapaksha; Thomas G Barclay; Milena Ginic-Markovic; Andrea R Gerson; Nikolai Petrovsky
Journal:  Carbohydr Polym       Date:  2014-10-23       Impact factor: 9.381

10.  An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.

Authors:  Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.